ERBB2 and breast carcinoma: Previously, We reported that the breast cancer patients with tumors expressing high levels of ER-α36 less benefited from TAM therapy than those with low levels of ER-α36 expression and ER-α36 expression is well correlated with HER2 expression [23], suggesting that gained ER-α36/HER2 expression is one of the underlying mechanisms of TAM resistance.